

CITATION REPORT

List of articles citing

Efficacy and safety of tadalafil monotherapy for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a meta-analysis

DOI: 10.1159/000351405

Urologia Internationalis, 2013, 91, 10-8.

Source: <https://exaly.com/paper-pdf/54859033/citation-report.pdf>

Version: 2024-04-11

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
30	Tadalafil monotherapy for benign prostatic hyperplasia. <i>Urologia Internationalis</i> , 2013 , 91, 487-8	1.9	
29	Management options for the treatment of benign prostatic hyperplasia with or without erectile dysfunction: a focus on tadalafil and patient considerations. <i>International Journal of General Medicine</i> , 2014 , 7, 271-6	2.3	3
28	A review of the use of tadalafil in the treatment of benign prostatic hyperplasia in men with and without erectile dysfunction. <i>Therapeutic Advances in Urology</i> , 2014 , 6, 135-47	3.2	28
27	Comparative Effectiveness and Safety of Monodrug Therapies for Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia: A Network Meta-analysis. <i>Medicine (United States)</i> , 2015 , 94, e974	1.8	34
26	Erectile Dysfunction in the Elderly. <i>Current Geriatrics Reports</i> , 2015 , 4, 33-43	1.3	3
25	Effects of pumpkin seed in men with lower urinary tract symptoms due to benign prostatic hyperplasia in the one-year, randomized, placebo-controlled GRANU study. <i>Urologia Internationalis</i> , 2015 , 94, 286-95	1.9	40
24	Current drug therapy of patients with BPH-LUTS with the special emphasis on PDE5 inhibitors. <i>Central European Journal of Urology</i> , 2016 , 69, 398-403	0.9	5
23	Benign prostatic hyperplasia: A clinical review. <i>JAAPA: Official Journal of the American Academy of Physician Assistants</i> , 2016 , 29, 19-23	0.8	10
22	Medical and Surgical Treatment Modalities for Lower Urinary Tract Symptoms in the Male Patient Secondary to Benign Prostatic Hyperplasia: A Review. <i>Seminars in Interventional Radiology</i> , 2016 , 33, 217-23	1.6	12
21	Antimuscarinics, β Agonists, and Phosphodiesterase Inhibitors in the Treatment of Male Lower Urinary Tract Symptoms: An Evolving Paradigm. <i>Urologic Clinics of North America</i> , 2016 , 43, 337-49	2.9	3
20	Latest Evidence on the Use of Phosphodiesterase Type 5 Inhibitors for the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia. <i>European Urology</i> , 2016 , 70, 124-133	10.2	85
19	Sexual Dysfunction Related to Drugs: a Critical Review. Part V: β Blocker and 5-ARI Drugs. <i>Pharmacopsychiatry</i> , 2016 , 49, 3-13	2	29
18	[Relationship between lower urinary tract symptoms in men and erectile dysfunction]. <i>Semergen</i> , 2016 , 42, 164-71	1.9	1
17	Effects of Tadalafil 5 mg Dosed Once Daily in Men with Premature Ejaculation. <i>Urologia Internationalis</i> , 2017 , 98, 210-214	1.9	8
16	Patologĳ prostĳica. <i>FMC Formacion Medica Continuada En Atencion Primaria</i> , 2017 , 24, 1-40	0	
15	Benign Prostatic Hyperplasia Treatment Options and Their Effects on Sexual Function. <i>Sexual Medicine Reviews</i> , 2017 , 5, 87-102	5.6	4
14	Treatment of lower urinary tract symptoms/benign prostatic hyperplasia and erectile dysfunction. <i>Aging Male</i> , 2018 , 21, 272-280	2.1	9

13	Factors affecting the efficacy and safety of phosphodiesterase 5 inhibitor and placebo in treatment for lower urinary tract symptoms: meta-analysis and meta-regression. <i>International Urology and Nephrology</i> , 2018 , 50, 35-47	2.3	3
12	Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia. <i>The Cochrane Library</i> , 2018 , 11, CD010060	5.2	8
11	Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia and Erectile Dysfunction. 2018 , 51-88		
10	Effect of phosphodiesterase 5 inhibitors on blood pressure. <i>The Cochrane Library</i> , 2019 ,	5.2	78
9	Disorders of the prostate: Lower urinary tract obstruction and prostatitis. 2019 , 135-164		
8	Efficacy of newer medications for lower urinary tract symptoms attributed to benign prostatic hyperplasia: a systematic review. <i>Aging Male</i> , 2019 , 22, 1-11	2.1	21
7	Prospective Multicenter Open-Label One-Arm Trial Investigating a Pumpkin Seed, Isoflavonoids, and Cranberry Mix in Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia: A Pilot Study. <i>Advances in Urology</i> , 2020 , 2020, 6325490	1.6	1
6	Which Drug to Discontinue 3 Months After Combination Therapy of Tadalafil plus Tamsulosin for Men with Lower Urinary Tract Symptom and Erectile Dysfunction? Results of a Prospective Observational Trial. <i>European Urology Focus</i> , 2021 , 7, 432-439	5.1	2
5	Sexual Dysfunctions Related to Drugs Used in the Management of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia: A Narrative Review on α -Blockers and 5-Alpha Reductase Inhibitors. <i>Uro</i> , 2021 , 1, 82-98		
4	Efficacy and Safety of 12-week Monotherapy With Once Daily 5 mg Tadalafil for Lower Urinary Tract Symptoms of Benign Prostatic Hyperplasia: Evidence-based Analysis. <i>Frontiers in Medicine</i> , 2021 , 8, 744012	4.9	0
3	Effectiveness and safety of Tadalafil-SZ (NJSC Northern Star) at 5 mg / day in patients with symptoms of voiding dysfunction due to prostatic hyperplasia. <i>Andrologia / Genitalnaa Chirurgia</i> , 2019 , 20, 72-77	0.5	
2	Part II : Interactive case: Combination therapies in benign prostatic hyperplasia. <i>JACCP Journal of the American College of Clinical Pharmacy</i> , 2022 , 5, 649-653	1.4	
1	Pharmakologische Therapie. 2022 , 85-103		0